Chronic obstructive pulmonary disease (COPD) management involves treatment of chronic stable COPD Chronic Obstructive Pulmonary Disease (COPD) Chronic obstructive pulmonary disease (COPD) is airflow limitation caused by an inflammatory response to inhaled toxins, often cigarette smoke. Alpha-1 antitrypsin deficiency and various occupational... read more and treatment of exacerbations Treatment of Acute COPD Exacerbation Chronic obstructive pulmonary disease (COPD) management involves treatment of chronic stable disease and treatment of exacerbations. Treatment of acute exacerbations involves Oxygen supplementation... read more .
Treatment of chronic stable COPD aims to prevent exacerbations and improve lung and physical function through
Enhancement of nutrition
Surgical treatment of COPD is indicated for selected patients. This may include lung volume reduction procedures or lung transplantation.
Smoking cessation Smoking Cessation Most smokers want to quit and have tried doing so with limited success. Effective interventions include cessation counseling and drug treatment, such as varenicline, bupropion, or a nicotine... read more is both extremely difficult and extremely important; it slows but does not halt the rate of FEV1 decline (see figure Changes in lung function in patients who quit smoking Changes in lung function (percentage of predicted FEV1) in patients who quit smoking compared with those who continue ) and increases long-term survival. Simultaneous use of multiple strategies is most effective:
Establishment of a quit date
Behavior modification techniques
Nicotine replacement therapy (by gum, transdermal patch, inhaler, lozenge, or nasal spray)
Varenicline or bupropion
Quit rates > 50% at 1 year have not been demonstrated even with the most effective interventions, such as use of bupropion combined with nicotine replacement or use of varenicline alone.
Changes in lung function (percentage of predicted FEV1) in patients who quit smoking compared with those who continue
During the first year, lung function improved in patients who quit smoking and declined in those who continued. Subsequently, the rate of decline in those who continued was twice that of those who quit. Function declined in those who relapsed and improved in those who quit regardless of when the change occurred. Based on data from Scanlon PD et al: Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease; the Lung Health Study. American Journal of Respiratory and Critical Care Medicine 161:381–390, 2000.
Drug Therapy for Stable COPD
Recommended drug therapy is summarized in the table Pharmacologic Treatment of COPD Pharmacologic Treatment of COPD .
Inhaled bronchodilators are the mainstay of COPD management; drugs include
These two classes of drugs are equally effective. Patients with mild Pulmonary function tests Chronic obstructive pulmonary disease (COPD) is airflow limitation caused by an inflammatory response to inhaled toxins, often cigarette smoke. Alpha-1 antitrypsin deficiency and various occupational... read more disease are treated only when symptomatic. Patients with moderate Pulmonary function tests Chronic obstructive pulmonary disease (COPD) is airflow limitation caused by an inflammatory response to inhaled toxins, often cigarette smoke. Alpha-1 antitrypsin deficiency and various occupational... read more to severe Pulmonary function tests Chronic obstructive pulmonary disease (COPD) is airflow limitation caused by an inflammatory response to inhaled toxins, often cigarette smoke. Alpha-1 antitrypsin deficiency and various occupational... read more COPD should be taking drugs from one or both of these classes regularly to improve pulmonary function and increase exercise capacity.
The frequency of exacerbations can be reduced with the use of anticholinergics, inhaled corticosteroids, or long-acting beta-agonists. However, there is no convincing evidence that regular bronchodilator use slows deterioration of lung function. The initial choice among short-acting beta-agonists, long-acting beta-agonists, anticholinergics, and combination beta-agonist and anticholinergic therapy is often a matter of tailoring cost and convenience to the patient’s preferences and symptoms.
For home treatment of chronic stable disease, drug administration by metered-dose inhaler or dry-powder inhaler is preferred over administration by nebulizer; home nebulizers are prone to contamination due to incomplete cleaning and drying. Therefore, nebulizers should be reserved for people who cannot coordinate activation of the metered-dose inhaler with inhalation or cannot develop enough inspiratory flow for dry powder inhalers.
For metered-dose inhalers, patients should be taught to exhale to functional residual capacity, inhale the aerosol slowly to total lung capacity, and hold the inhalation for 3 to 4 seconds before exhaling. Spacers help ensure optimal delivery of drug to the distal airways and reduce the importance of coordinating activation of the inhaler with inhalation. Some spacers alert patients if they are inhaling too rapidly. New or not recently used metered-dose inhalers require 2 to 3 priming doses (different manufacturers have slightly different recommendations for what is considered "not recently used," ranging from 3 to 14 days).
Pharmacologic Treatment of COPD
Timing of Therapy
Dyspnea without exacerbations*, †
Exacerbations with or without dyspnea‡
LAC or LABA
LAC or LABA
LABA + LAC or LABA + ICS
LABA + LAC or LABA + ICS
LABA + LAC + ICS
LABA + LAC + ICS
* For persistent dyspnea, consider changing the inhalation device or drug. Also evaluate for other causes of dyspnea.
† May need to de-escalate ICS if the patient develops pneumonia or does not respond to treatment.
‡ For recurrent exacerbations,add either a PDE4 inhibitor (eg, roflumilast) or long-term azithromycin. ICS is most effective in patients with eosinophilia. Roflumilast is indicated in patients with COPD with chronic bronchitis. Azithromycin is less effective in current smokers.
LABA = Long-acting beta agonist; LAC = long-acting anticholinergic; ICS = inhaled corticosteroid; PDE4 = phosphodiesterase-4 inhibitor.
Data from Figure 4.4 of the Global Initiative for Chronic Obstructive Lung Disease (GOLD): 2021 Global Strategy for the Diagnosis, Management and Prevention of COPD. Available at http://www.goldcopd.org.
Beta-agonists relax bronchial smooth muscle and increase mucociliary clearance. Albuterol aerosol, 2 puffs (90 to 100 mcg/puff) inhaled from a metered-dose inhaler 4 to 6 times a day as needed, is usually the drug of choice.
Long-acting beta-agonists are preferable for patients with nocturnal symptoms or for those who find frequent dosing inconvenient. Options include salmeterol powder, 1 puff (50 mcg) inhaled twice a day, indacaterol 1 puff (75 mcg) inhaled once a day (150 mcg once a day in Europe), and olodaterol 2 puffs once a day at the same time each day. Vilanterol is available in combination with an inhaled corticosteroid. Also available are nebulized forms of arformoterol and formoterol. The dry-powder formulations may be more effective for patients who have trouble coordinating use of a metered-dose inhaler.
Patients should be taught the difference between short-acting and long-acting drugs, because long-acting drugs that are used as needed or more than twice a day increase the risk of cardiac arrhythmias Overview of Arrhythmias The normal heart beats in a regular, coordinated way because electrical impulses generated and spread by myocytes with unique electrical properties trigger a sequence of organized myocardial... read more .
Adverse effects commonly result from use of any beta-agonist and include tremor, anxiety, tachycardia, and mild, temporary hypokalemia.
Anticholinergics (antimuscarinics) relax bronchial smooth muscle through competitive inhibition of muscarinic receptors (M1, M2, and M3).
Ipratropium is a short-acting anticholinergic; dose is 2 to 4 puffs (17 mcg/puff) from a metered-dose inhaler every 4 to 6 hours. Ipratropium has a slower onset of action (within 30 minutes; peak effect in 1 to 2 hour), so a beta-agonist is often prescribed with it in a single combination inhaler or as a separate as-needed rescue drug.
Tiotropium is a long-acting quaternary anticholinergic inhaled as a powder formulation (18 mcg/puff) and soft mist inhaler (2.5 mcg/puff). Dose is 1 puff (18 mcg) once a day by dry powder inhaler and 2 puffs (5 mcg) once a day by soft mist inhaler. Aclidinium bromide is available as a multidose dry-powder inhaler. Dose is 1 puff (400 mcg/puff) twice a day. Aclidinium is also available in combination with a long-acting beta-agonist as a dry-powder inhaler. Umeclidinium can be used as a once a day combination with vilanterol (a long-acting beta-agonist) in a dry-powder inhaler. Glycopyrrolate (an anticholinergic) can be used twice a day in combination with indacaterol or formoterol (long-acting beta-agonists) in a dry-powder or metered-dose inhaler. Revefenacin is given once a day via nebulizer.
Adverse effects of all anticholinergics are pupillary dilation (and risk of triggering or worsening acute angle closure glaucoma Angle-Closure Glaucoma Angle-closure glaucoma is glaucoma associated with a physically obstructed anterior chamber angle, which may be chronic or, rarely, acute. Symptoms of acute angle closure are severe ocular pain... read more ), urinary retention, and dry mouth.
Corticosteroids are often part of treatment. Inhaled corticosteroids seem to reduce airway inflammation, reverse beta-receptor down-regulation, and inhibit leukotriene and cytokine production. They do not alter the course of pulmonary function decline in patients with COPD who continue to smoke, but they do relieve symptoms and improve short-term pulmonary function in some patients, are additive to the effect of bronchodilators, and diminish the frequency of COPD exacerbations. They are indicated for patients who have repeated exacerbations or symptoms despite optimal bronchodilator therapy. Inhaled corticosteroids are of greatest benefit in patients who have eosinophilia Eosinophilia Eosinophilia is defined as a peripheral blood eosinophil count > 500/mcL (> 0.5 × 109/L). Causes and associated disorders are myriad but often represent an allergic reaction or... read more . In patients with exacerbations, addition of an inhaled corticosteroid reduces exacerbation frequency and prolongs survival (1, 2 Drug therapy references Chronic obstructive pulmonary disease (COPD) management involves treatment of chronic stable COPD and treatment of exacerbations. Treatment of chronic stable COPD aims to prevent exacerbations... read more ). Dose depends on the drug; examples include fluticasone 500 to 1000 mcg/day and beclomethasone 400 to 2000 mcg/day.
The long-term risks of inhaled corticosteroids in older people are not proved but probably include osteoporosis Osteoporosis Osteoporosis is a progressive metabolic bone disease that decreases bone mineral density (bone mass per unit volume), with deterioration of bone structure. Skeletal weakness leads to fractures... read more , cataract formation Cataract A cataract is a congenital or degenerative opacity of the lens. The main symptom is gradual, painless vision blurring. Diagnosis is by ophthalmoscopy and slit-lamp examination. Treatment is... read more , and an increased risk of nonfatal pneumonia Overview of Pneumonia Pneumonia is acute inflammation of the lungs caused by infection. Initial diagnosis is usually based on chest x-ray and clinical findings. Causes, symptoms, treatment, preventive measures, and... read more . Long-term users therefore should undergo periodic ophthalmologic and bone densitometry screening if indicated (eg, by a history of changes in night vision, frailty, or bone fractures) and should possibly receive supplemental calcium, vitamin D, and a bisphosphonate as indicated.
De-escalation of inhaled corticosteroid therapy may be necessary if patients develop pneumonia or do not respond to treatment.
Combinations of a long-acting beta-agonist and an inhaled corticosteroid are more effective than either drug alone in the treatment of chronic stable disease.
Oral or systemic corticosteroids should usually not be used to treat chronic stable COPD.
Theophylline plays only a small role in the treatment of chronic stable COPD now that safer, more effective drugs are available. Theophylline decreases smooth muscle spasm, enhances mucociliary clearance, improves right ventricular function, and decreases pulmonary vascular resistance and arterial pressure. Its mode of action is poorly understood but appears to differ from that of beta-2-agonists and anticholinergics. Its role in improving diaphragmatic function and dyspnea during exercise is controversial.
Theophylline can be used for patients who have not adequately responded to inhaled drugs and who have shown symptomatic benefit from a trial of the drug. Serum levels need not be monitored unless the patient does not respond to the drug, develops symptoms of toxicity, or is questionably adherent; slowly absorbed oral theophylline preparations, which require less frequent dosing, enhance adherence.
Toxicity is common and includes sleeplessness and gastrointestinal upset, even at low blood levels. More serious adverse effects, such as supraventricular and ventricular arrhythmias and seizures, tend to occur at blood levels > 20 mg/L (111 micromol/L).
Hepatic metabolism of theophylline varies greatly and is influenced by genetic factors, age, cigarette smoking, hepatic dysfunction, diet, and some drugs, such as macrolide and fluoroquinolone antibiotics and nonsedating histamine 2 blockers.
Phosphodiesterase-4 inhibitors are more specific than theophylline for pulmonary phosphodiesterase and have fewer adverse effects. They have anti-inflammatory properties and are mild bronchodilators. Phosphodiesterase-4 inhibitors such as roflumilast can be used in addition to other bronchodilators for reduction of exacerbations in patients who have COPD with chronic bronchitis. Roflumilast should be started at a oral dose of 250 mcg once a day and increased to 500 mcg once a day as tolerated.
Common adverse effects include nausea, headache, and weight loss, but these effects may subside with continued use.
Long-term azithromycin therapy is an effective adjunct to prevent COPD exacerbations in patients who are prone to repeated or severe exacerbations, particularly those who are not currently smoking. A dose of 250 mg orally once a day has demonstrated efficacy. Erythromycin 250 mg orally twice or 3 times a day has also been found effective.
Drug therapy references
1. Lipson DA, Crim C, Criner GJ, et al: Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 201(12):1508–1516, 2020. doi: 10.1164/rccm.201911-2207OC
2. Rabe KF, Martinez FJ, Ferguson GT, et al: Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med 383(1):35–48, 2020. doi: 10.1056/NEJMoa1916046
Oxygen Therapy for Stable COPD
Long-term oxygen therapy prolongs life in patients with COPD whose PaO2 is chronically < 55 mm Hg. Continual 24-hour use is more effective than a 12-hour nocturnal regimen. Oxygen therapy does the following:
Brings hematocrit toward normal levels
Improves neuropsychologic factors, possibly by facilitating sleep
Ameliorates pulmonary hemodynamic abnormalities
Increases exercise tolerance in many patients
Oxygen saturation should be measured during exercise and while at rest. Similarly, a sleep study should be considered for patients with advanced COPD who do not meet the criteria for long-term oxygen therapy while they are awake (see table Indications for Long-Term Oxygen Therapy in COPD Indications for Long-Term Oxygen Therapy in COPD ) but whose clinical assessment suggests pulmonary hypertension Pulmonary Hypertension Pulmonary hypertension is increased pressure in the pulmonary circulation. It has many secondary causes; some cases are idiopathic. In pulmonary hypertension, pulmonary vessels may become constricted... read more in the absence of daytime hypoxemia. Nocturnal oxygen may be prescribed if a sleep study shows episodic desaturation to ≤ 88%. Such treatment prevents progression of pulmonary hypertension Pulmonary Hypertension Pulmonary hypertension is increased pressure in the pulmonary circulation. It has many secondary causes; some cases are idiopathic. In pulmonary hypertension, pulmonary vessels may become constricted... read more , but its effects on survival are unknown. Patients with moderate hypoxemia above 88% or exercise desaturation may benefit symptomatically from oxygen, but there is no improvement in survival or reduction in hospitalizations (1 Oxygen therapy reference Chronic obstructive pulmonary disease (COPD) management involves treatment of chronic stable COPD and treatment of exacerbations. Treatment of chronic stable COPD aims to prevent exacerbations... read more ).
Some patients need supplemental oxygen during air travel because flight cabin pressure in commercial airliners is below sea level air pressure (often equivalent to 1830 to 2400 m [6000 to 8000 ft]). Eucapnic COPD patients who have a PaO2> 68 mm Hg at sea level generally have an in-flight PaO2> 50 mm Hg and do not require supplemental oxygen. All patients with COPD with a PaO2 ≤ 68 mm Hg at sea level, hypercapnia, significant anemia (hematocrit < 30), or a coexisting heart or cerebrovascular disorder should use supplemental oxygen during long flights and should notify the airline when making their reservation. Now that approved portable oxygen concentrators are ubiquitous, very few airlines still provide oxygen. Patients are advised to rent or purchase a portable oxygen concentrator for use during air travel, including enough spare batteries to account for the flight time and possible delays.
Indications for Long-Term Oxygen Therapy in COPD
PaO2 ≤ 55 mm Hg or SaO2 ≤ 88%* in patients receiving optimal medical regimen for at least 30 days†
PaO2 = 55 to 59 mm Hg or SaO2 ≤ 89%* for patients with cor pulmonale Cor Pulmonale Cor pulmonale is right ventricular (RV) enlargement secondary to a lung disorder that causes pulmonary artery hypertension. Right ventricular failure follows. Findings include peripheral edema... read more or erythrocytosis ( > 55%)
Can be considered for patients with exercise desaturation if there is symptomatic improvement; however, there is no improvement in survival or hospitalization. May also be considered for patients with nocturnal desaturation.‡
* Arterial oxygen levels are measured at rest during air breathing.
† Patients who are recovering from an acute respiratory illness and who meet the listed criteria should be given oxygen and rechecked while breathing room air after 60 to 90 days.
‡ See also Long-Term Oxygen Treatment Trial Research Group: A randomized trial of long-term oxygen for COPD with moderate desaturation. N Engl J Med 375:1617–1627, 2016.
Hct = hematocrit; PaO2 = arterial oxygen partial pressure; SaO2 = oxygen saturation.
Oxygen is administered by nasal cannula at a flow rate sufficient to achieve a PaO2 > 60 mm Hg (oxygen saturation > 90%), usually ≤ 3 L/minute at rest (frequently higher at higher altitudes, such as in Denver). Oxygen is supplied by electrically driven oxygen concentrators, liquid oxygen systems, or cylinders of compressed gas. Stationary concentrators, which limit mobility but are the least expensive, are preferable for patients who spend most of their time at home. Such patients require small oxygen tanks for backup in case of an electrical failure and for portable use. Portable concentrators that allow mobility can be used for patients who do not require high flow rates.
A liquid system is preferable for patients who spend much time out of their home. Portable canisters of liquid oxygen are easier to carry and have more capacity than portable cylinders of compressed gas. Large compressed oxygen cylinders are the most expensive way of providing oxygen and should be used only if no other source is available. All patients must be taught the dangers of smoking during oxygen use.
Various oxygen-conserving devices can reduce the amount of oxygen used by the patient, either by using a reservoir system or by permitting oxygen flow only during inspiration. Systems with these devices may correct resting hypoxemia as effectively as continuous flow devices. However, intermittent flow devices may not be as effective as continuous flow for exercise-associated hypoxemia.
Oxygen therapy reference
1. Long-Term Oxygen Treatment Trial Research Group: A randomized trial of long-term oxygen for COPD with moderate desaturation. N Engl J Med 375:1617–1627, 2016.
All patients with COPD should be given annual influenza vaccinations Influenza Vaccine Based on recommendations by the World Health Organization and the Centers for Disease Control and Prevention (CDC), vaccines for influenza are modified annually to include the most prevalent... read more . If a patient' COPD renders them at increased risk of respiratory complications from influenza, prophylactic treatment with a neuraminidase inhibitor (oseltamivir or zanamivir) is recommended, after close exposure to influenza-infected people. Treatment with a neuraminidase inhibitor should be started at the first sign of an influenza-like illness and within 2 days of the exposure. Alternatively, baloxavir marboxil, an endonuclease inhibitor, may be considered for uncomplicated influenza in patients ≥ 12 years who have been symptomatic for no more than 48 hours.
Pneumococcal polysaccharide vaccine Pneumococcal Vaccine Pneumococcal disease (eg, otitis media, pneumonia, sepsis, meningitis) is caused by some of the > 90 serotypes of Streptococcus pneumoniae (pneumococci). Vaccines are directed against... read more and pneumococcal conjugate vaccine Preparations Pneumococcal disease (eg, otitis media, pneumonia, sepsis, meningitis) is caused by some of the > 90 serotypes of Streptococcus pneumoniae (pneumococci). Vaccines are directed against... read more should be administered because they are effective in reducing community-acquired pneumonia and invasive pneumococcal infections in older adults.
Nutrition in Stable COPD
COPD patients are at risk of weight loss and nutritional deficiencies because of a higher energy cost of daily activities; reduced caloric intake relative to need because of dyspnea; and the catabolic effect of inflammatory cytokines such as tumor necrosis factor (TNF)-alpha. Generalized muscle strength and efficiency of oxygen use are impaired. Patients with poorer nutritional status have a worse prognosis, so it is prudent to recommend a balanced diet with adequate caloric intake in conjunction with exercise to prevent or reverse undernutrition and muscle atrophy. Split-meal feeding can be helpful.
Excessive weight gain should be avoided, and obese patients should strive to gradually reduce body fat.
Studies of nutritional supplementation alone have not shown improvement in pulmonary function or exercise capacity. Trials of appetite stimulants, anabolic steroids, growth hormone supplementation, and TNF antagonists in reversing undernutrition and improving functional status and prognosis in COPD have been disappointing.
Pulmonary Rehabilitation in Stable COPD
Pulmonary rehabilitation Pulmonary Rehabilitation Pulmonary rehabilitation is the use of supervised exercise, education, support, and behavioral intervention to improve functional capacity and enhance quality of life in patients with chronic... read more programs serve as adjuncts to drug treatment to improve physical function; many hospitals and health care organizations offer formal multidisciplinary rehabilitation programs. Pulmonary rehabilitation includes exercise, education, and behavioral interventions. Treatment should be individualized; patients and family members are taught about COPD and medical treatments, and patients are encouraged to take as much responsibility for personal care as possible.
The benefits of rehabilitation are greater independence and improved quality of life and exercise capacity. Pulmonary rehabilitation typically does not improve pulmonary function. A carefully integrated rehabilitation program helps patients with severe COPD accommodate to physiologic limitations while providing realistic expectations for improvement. Patients with severe disease require a minimum of 3 months of rehabilitation to benefit and should continue with maintenance programs.
An exercise program can be helpful in the home, in the hospital, or in institutional settings. Graded exercise can ameliorate skeletal muscle deconditioning resulting from inactivity or prolonged hospitalization for respiratory failure. Specific training of respiratory muscles is less helpful than general aerobic conditioning.
A typical training program begins with slow walking on a treadmill or unloaded cycling on an ergometer for a few minutes. Duration and exercise load are progressively increased over 4 to 6 weeks until the patient can exercise for 20 to 30 minutes nonstop with manageable dyspnea. Patients with very severe COPD can usually achieve an exercise regimen of walking for 30 minutes at 1 to 2 mph (1.6 to 3.2 km per hour). Maintenance exercise should be done 3 to 4 times/week to maintain fitness levels. Oxygen saturation is monitored, and supplemental oxygen is provided as needed.
Upper extremity resistance training helps the patient in doing daily tasks (eg, bathing, dressing, house cleaning). The usual benefits of exercise are modest increases in lower extremity strength, endurance, and maximum oxygen consumption.
Patients should be taught ways to conserve energy during activities of daily living and to pace their activities. Difficulties in sexual function should be discussed and advice should be given on using energy-conserving techniques for sexual gratification.
Surgery in Stable COPD
Surgical options for treatment of severe COPD include
Lung volume reduction
Lung volume reduction surgery
Lung volume reduction surgery consists of resecting nonfunctioning emphysematous areas. The procedure improves lung function, exercise tolerance, and quality of life in patients with severe, predominantly upper-lung emphysema who have low baseline exercise capacity after pulmonary rehabilitation. Mortality is increased in the first 90 days after lung volume reduction surgery, but survival is higher at 5 years.
The effect on arterial blood gas measurements is variable and not predictable, but most patients who require oxygen therapy before surgery continue to need it. Improvement is less than that with lung transplantation. The mechanism of improvement is believed to be enhanced lung recoil and improved diaphragmatic function.
Operative mortality is about 5%. The best candidates for lung volume reduction surgery are patients with an FEV1 20 to 40% of predicted, a DLCO > 20% of predicted, significantly impaired exercise capacity, heterogeneous pulmonary disease on CT with an upper-lobe predominance, PaCO2 < 50 mm Hg, and absence of severe pulmonary hypertension and coronary artery disease.
Rarely, patients have extremely large bullae that compress the functional lung. These patients can be helped by surgical resection of these bullae, with resulting relief of symptoms and improved pulmonary function. Generally, resection is most beneficial for patients with bullae affecting more than one third of a hemithorax and an FEV1 about half of the predicted normal value. Improved pulmonary function is related to the amount of normal or minimally diseased lung tissue that was compressed by the resected bullae. Serial chest x-rays and CT scans are the most useful procedures for determining whether a patient’s functional status is due to compression of viable lung by bullae or to generalized emphysema. A markedly reduced DLCO (< 40% predicted) indicates widespread emphysema and suggests a poorer outcome from surgical resection.
Lung transplantation Lung and Heart-Lung Transplantation Lung or heart-lung transplantation is an option for patients who have respiratory insufficiency or failure and who remain at risk of death despite optimal medical treatment. (See also Overview... read more can be single or double. Perioperative complications tend to be lower with single-lung transplantation, but some evidence shows that survival time is increased with double-lung transplantation. Candidates for transplantation are patients < 65 years with an FEV1 < 25% predicted after bronchodilator therapy or with severe pulmonary hypertension. The goal of lung transplantation is to improve quality of life, because survival time is not necessarily increased. The 5-year survival after transplantation for emphysema is 45 to 60%. Lifelong immunosuppression is required, with the attendant risk of opportunistic infections.
Endobronchial valves that cause atelectasis of emphysematous target regions of the lung in selected patients who do not have collateral ventilation to these regions are available in selected centers. Placement of an endobronchial valve is an alternative to lung volume reduction surgery in some patients. Surgical lung volume reduction is usually bilateral, whereas bronchoscopic procedures are usually unilateral and therefore result in less improvement.
Relieve symptoms of chronic obstructive pulmonary disease rapidly with primarily short-acting beta-adrenergic drugs and decrease exacerbations with inhaled corticosteroids, long-acting beta-adrenergic drugs, long-acting anticholinergic drugs, or a combination.
Encourage smoking cessation using multiple interventions (eg, behavior modification, support groups, nicotine replacement, drug therapy).
Optimize use of supportive treatments (eg, nutrition, pulmonary rehabilitation, self-directed exercise).
Drugs Mentioned In This Article
|Drug Name||Select Trade|
|Aplenzin, Budeprion SR , Budeprion XL , Buproban, Forfivo XL, Wellbutrin, Wellbutrin SR, Wellbutrin XL, Zyban|
|Accuneb, ProAir digihaler, Proair HFA, ProAir RespiClick, Proventil, Proventil HFA, Proventil Repetabs, Respirol , Ventolin, Ventolin HFA, Ventolin Syrup, Volmax, VoSpire ER|
|Serevent, Serevent Diskus|
|Atrovent, Atrovent HFA|
|Spiriva HandiHaler, Spiriva Respimat|
|Cuvposa, Dartisla, Glycate, GLYRX-PF, Lonhala Magnair, Robinul, Robinul Forte, Seebri Neohaler|
|ArmonAir Digihaler, ARMONAIR RESPICLICK, ARNUITY ELLIPTA, BESER, ClariSpray, Cutivate, Flonase, Flonase Allergy Relief, Flonase Sensimist , Flovent, Flovent Diskus , Flovent HFA, Flovent Rotadisk, Veramyst, XHANCE|
|Beclovent, Beconase AQ, Qnasl, Qnasl Children's, QVAR, QVAR RediHaler, Vancenase, Vancenase AQ, Vanceril|
|Calcidol, Calciferol, D3 Vitamin, DECARA, Deltalin, Dialyvite Vitamin D, Dialyvite Vitamin D3, Drisdol, D-Vita, Enfamil D-Vi-Sol, Ergo D, Fiber with Vitamin D3 Gummies Gluten-Free, Happy Sunshine Vitamin D3, MAXIMUM D3, PureMark Naturals Vitamin D, Replesta, Replesta Children's, Super Happy SUNSHINE Vitamin D3, Thera-D 2000, Thera-D 4000, Thera-D Rapid Repletion, THERA-D SPORT, UpSpring Baby Vitamin D, UpSpring Baby Vitamin D3, YumVs, YumVs Kids ZERO, YumVs ZERO|
|Elixophyllin, Quibron T, Quibron T/SR, Respbid, Slo-Bid, Slo-Phyllin, Theo X, Theo-24, Theo-Bid Duracap, TheoCap, Theochron, Theo-Dur, Theo-Dur Sprinkle , Theolair, Theolair SR, Theovent LA, T-Phyl, Uni-Dur, Uniphyl|
|Azasite, Zithromax, Zithromax Powder, Zithromax Single-Dose , Zithromax Tri-Pak, Zithromax Z-Pak, Zmax, Zmax Pediatric|
|A/T/S, Akne-mycin, E.E.S., Emcin Clear , EMGEL, E-Mycin, ERYC, Erycette, Eryderm , Erygel, Erymax, EryPed, Ery-Tab, Erythra Derm , Erythrocin, Erythrocin Lactobionate, Erythrocin Stearate, Ilosone, Ilotycin, My-E, PCE, PCE Dispertab , Romycin, Staticin, T-Stat|
|Xofluza, Xofluza Granules|
|Commit, Habitrol, Nicoderm CQ, NICOrelief , Nicorette, Nicotrol, Nicotrol NS|